HK1219048A1 - 前蛋白轉化酶枯草桿菌蛋白酶/ 變構結合配體來調節低密度脂蛋白 血清水平 - Google Patents
前蛋白轉化酶枯草桿菌蛋白酶/ 變構結合配體來調節低密度脂蛋白 血清水平Info
- Publication number
- HK1219048A1 HK1219048A1 HK16107087.1A HK16107087A HK1219048A1 HK 1219048 A1 HK1219048 A1 HK 1219048A1 HK 16107087 A HK16107087 A HK 16107087A HK 1219048 A1 HK1219048 A1 HK 1219048A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pcsk9
- ldl
- kexin
- mudulate
- levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Developmental Biology & Embryology (AREA)
- Physiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361765423P | 2013-02-15 | 2013-02-15 | |
US201361836381P | 2013-06-18 | 2013-06-18 | |
PCT/US2014/016640 WO2014127316A2 (en) | 2013-02-15 | 2014-02-15 | Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1219048A1 true HK1219048A1 (zh) | 2017-03-24 |
Family
ID=51354696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16107087.1A HK1219048A1 (zh) | 2013-02-15 | 2016-06-20 | 前蛋白轉化酶枯草桿菌蛋白酶/ 變構結合配體來調節低密度脂蛋白 血清水平 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2956154A4 (zh) |
JP (1) | JP2016508722A (zh) |
KR (1) | KR20150127622A (zh) |
CN (1) | CN105378159A (zh) |
AU (1) | AU2014216091A1 (zh) |
CA (1) | CA2901436A1 (zh) |
HK (1) | HK1219048A1 (zh) |
IL (1) | IL240583A0 (zh) |
SG (1) | SG11201506336XA (zh) |
WO (1) | WO2014127316A2 (zh) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
DK3143037T3 (da) | 2014-05-16 | 2021-09-20 | Protagonist Therapeutics Inc | Alpha4beta7-integrin-thioether-peptidantagonister |
EP3169403B9 (en) | 2014-07-17 | 2024-07-03 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
JP2017528448A (ja) * | 2014-08-21 | 2017-09-28 | エスアールエックス カーディオ,エル エル シー | プロタンパク質コンバターゼであるスブチリシン/ケキシンタイプ9(pcsk9)のタンパク質活性のモジュレーションのための、結合リガンドとしての小分子の組成物およびその使用方法 |
AU2015328002A1 (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
MA41022A (fr) * | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
EP3337788A4 (en) | 2015-08-21 | 2019-03-27 | Portola Pharmaceuticals, Inc. | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE |
WO2017034990A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity |
US10821106B2 (en) | 2015-08-21 | 2020-11-03 | Srx Cardio, Llc | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity |
WO2017058113A1 (en) * | 2015-09-28 | 2017-04-06 | Agency For Science, Technology And Research | Coating for metal nanoparticles |
WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
EP3432906A4 (en) | 2016-03-23 | 2020-04-01 | Protagonist Therapeutics, Inc. | METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS |
KR102449308B1 (ko) | 2016-06-24 | 2022-10-04 | 에프. 호프만-라 로슈 아게 | 심혈관 질환의 치료를 위한 조성물 및 방법 |
TW201823222A (zh) * | 2016-12-23 | 2018-07-01 | 財團法人生物技術開發中心 | 化合物、醫藥組成物及其用途 |
EP4092038A1 (en) | 2017-09-11 | 2022-11-23 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
US11753443B2 (en) | 2018-02-08 | 2023-09-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
CA3125765A1 (en) | 2019-01-18 | 2020-07-23 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
MX2022000397A (es) | 2019-07-10 | 2022-04-25 | Protagonist Therapeutics Inc | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
CR20220332A (es) | 2020-01-15 | 2022-11-28 | Janssen Biotech Inc | Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias |
CA3168135A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
PE20240631A1 (es) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Composiciones de inhibidores peptidicos del receptor de interleucina-23 |
US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
CA3213636A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7928189B2 (en) * | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
PL2483266T3 (pl) * | 2009-10-01 | 2015-08-31 | Cadila Healthcare Ltd | Związki do leczenia dyslipidemii i chorób pokrewnych |
CN102206249B (zh) * | 2011-04-26 | 2013-07-03 | 中国农业科学院哈尔滨兽医研究所 | 乙型脑炎病毒ns1蛋白特异性b细胞抗原表位多肽及其应用 |
-
2014
- 2014-02-15 CA CA2901436A patent/CA2901436A1/en not_active Abandoned
- 2014-02-15 WO PCT/US2014/016640 patent/WO2014127316A2/en active Application Filing
- 2014-02-15 CN CN201480017801.7A patent/CN105378159A/zh active Pending
- 2014-02-15 SG SG11201506336XA patent/SG11201506336XA/en unknown
- 2014-02-15 JP JP2015558178A patent/JP2016508722A/ja active Pending
- 2014-02-15 EP EP14751148.9A patent/EP2956154A4/en not_active Withdrawn
- 2014-02-15 AU AU2014216091A patent/AU2014216091A1/en not_active Abandoned
- 2014-02-15 KR KR1020157025152A patent/KR20150127622A/ko not_active Application Discontinuation
-
2015
- 2015-08-13 IL IL240583A patent/IL240583A0/en unknown
-
2016
- 2016-06-20 HK HK16107087.1A patent/HK1219048A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2956154A2 (en) | 2015-12-23 |
CA2901436A1 (en) | 2014-08-21 |
WO2014127316A3 (en) | 2014-10-09 |
WO2014127316A2 (en) | 2014-08-21 |
CN105378159A (zh) | 2016-03-02 |
IL240583A0 (en) | 2015-09-24 |
AU2014216091A1 (en) | 2015-09-03 |
KR20150127622A (ko) | 2015-11-17 |
SG11201506336XA (en) | 2015-09-29 |
JP2016508722A (ja) | 2016-03-24 |
WO2014127316A4 (en) | 2014-12-04 |
EP2956154A4 (en) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1219048A1 (zh) | 前蛋白轉化酶枯草桿菌蛋白酶/ 變構結合配體來調節低密度脂蛋白 血清水平 | |
HK1243075A1 (zh) | 使前蛋白轉化酶枯草溶菌素/ kexin 9型(pcsk9)減少的方法 | |
ZA201409210B (en) | Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors | |
IL266066A (en) | Methods for preventing cardiovascular events by reducing the protein proprotein convertase subtilisin kexin 9 | |
HK1257523A1 (zh) | 用於治療前蛋白轉化酶枯草桿菌蛋白酶kexin(pcsk9)基因相關障礙的方法和組合物 | |
HK1207592A1 (zh) | 含有抗 抗體的穩定製劑 | |
HK1216841A1 (zh) | 用前蛋白轉化酶枯草溶菌素 抑制劑降低殘餘膽固醇及其他脂蛋白組分含量的方法 | |
EP2968266A4 (en) | KEXINE ANTI-PROPERTY CONVERTASE CONVERTASE COMPOUNDS TYPE 9 (ANTI-PCSK9) AND METHODS OF USING THE SAME FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES | |
IL231011B (en) | Methods for reducing lipoprotein (a) levels by administering proprotein convertase subtilisin kexin - 9 (9pcsk) | |
HK1202804A1 (zh) | 使用抗 抗體的治療 | |
MX2016006226A (es) | Regimenes de dosificacion para uso con inhibidores de pcsk9. | |
DK2215124T4 (da) | Antigenbindende proteiner til proprotein convertase subtilisin kexin type 9 (pcsk9) | |
EP3182971A4 (en) | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity | |
ZA201307499B (en) | Compositions and methods comprising serine protease variants | |
IL240437B (en) | A fraction of fibrin serum is rich in platelets | |
HK1257102A1 (zh) | 苯基哌嗪前蛋白轉化酶枯草桿菌蛋白酶/kexin9型(pcsk9)調節劑及其應用 | |
EP2771358A4 (en) | ELIMINATION OF VIRAL AGENTS IN MIXED MODE CHROMATOGRAPHY | |
EP2682123A4 (en) | BIOLOGICALLY EFFECTIVE FOOD ADDITIVE FOR NORMALIZING THE FUNCTION OF THE THYROID | |
MX2017011879A (es) | Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". | |
GB201306127D0 (en) | Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) | |
HK1218140A1 (zh) | 凝乳性天冬氨酸蛋白酶組合物 | |
GB201602153D0 (en) | Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) | |
ZA201507890B (en) | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) | |
GB201107200D0 (en) | Methods of identifying FOXM1 ligands | |
GB201203500D0 (en) | Cheese type products - vegatable oil and healthy additive, addition |